BioTek Instruments is pleased to announce its collaboration with MilliporeSigma on an integrated solution for long-term live cell experiments and dynamic time-lapse analyses, including automated cell perfusion and imaging. The solution leverages each company’s respective expertise, and consists of BioTek’s new Lionheart™ FX Automated Live Cell Imager and MilliporeSigma’s new CellASIC® ONIX2 Microfluidic System.

This collaborative solution was introduced at the American Association of Cancer Research (AACR) Annual Meeting recently held April 16-20, 2016 in New Orleans, LA.

The Lionheart FX Automated Live Cell Imager is optimized for live cell microscopy, with up to 100x magnification and brightfield, color brightfield, phase contrast and fluorescence channels. Gen5™ 3.0 Software powers Lionheart FX, and allows quick and effortless cell image capture, analysis, annotation and time lapse video production.

The CellASIC® ONIX2 Microfluidic System automates dynamic environmental control over live cells, with high precision controls, expansive functionality and user-friendly operation. Its unique microfluidics technology provides hands-free control over drug addition, gas, temperature, media and more, along with customizable media flow rates.

BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. These technologies are used to aid life science research, facilitate drug discovery, provide rapid and cost-effective analysis, and enable sensitive, accurate quantification of molecules across diverse applications. BioTek espouses a “Think Possible” approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations. As such, they are often honored for local accomplishments and technological innovations, including Best Places to Work in Vermont, North American New Product Innovation Award for Workflow Solutions in Life Sciences, and Scientists' Choice Awards®: Drug Discovery Product of the Year and Best New Life Sciences Product.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $130 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials - and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada.

 

For additional information, contact:

Chere Griffin
Expression Marcom, LLC
908-818-9463
cgriffin@expressionmarcom.com

Karen Tiano
MilliporeSigma
978-495-0093
karen.tiano@emdmillipore.com